TransMedics Group (NASDAQ:TMDX) Receives “Neutral” Rating from JPMorgan Chase & Co.

TransMedics Group (NASDAQ:TMDX)‘s stock had its “neutral” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a research note issued on Tuesday,Benzinga reports. They currently have a $75.00 price target on the stock, down from their prior price target of $116.00. JPMorgan Chase & Co.‘s target price indicates a potential upside of 16.79% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Canaccord Genuity Group reduced their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Oppenheimer restated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Performance

Shares of TMDX opened at $64.22 on Tuesday. The company’s 50 day moving average price is $94.37 and its 200 day moving average price is $130.78. TransMedics Group has a 52 week low of $63.42 and a 52 week high of $177.37. The company has a market capitalization of $2.16 billion, a PE ratio of 68.32 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. Research analysts expect that TransMedics Group will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $3,089,766.32. This represents a 12.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 19,417 shares of company stock worth $2,240,738 in the last ninety days. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of TMDX. International Assets Investment Management LLC bought a new stake in TransMedics Group in the 2nd quarter valued at $47,000. USA Financial Formulas bought a new stake in TransMedics Group in the 3rd quarter valued at $55,000. Quarry LP grew its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI grew its holdings in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the last quarter. Finally, Signaturefd LLC grew its holdings in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.